Sweden Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Sweden recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Sweden recombinant protein therapeutics cdmo market highlights
- The Sweden recombinant protein therapeutics cdmo market generated a revenue of USD 393.4 million in 2023 and is expected to reach USD 919.1 million by 2030.
- The Sweden market is expected to grow at a CAGR of 12.9% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 393.4 million |
| Market revenue in 2030 | USD 919.1 million |
| Growth rate | 12.9% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Sweden accounted for 1.9% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,892.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.38% in 2023. Horizon Databook has segmented the Sweden recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Sweden holds a strong position in drug development and discovery from phase I to phase III trials. The country's growing number of clinical trials is driving market growth. Sweden's life sciences industry is very strategic, focusing on world-class innovation and excellent R&D. This can be observed through the significant increase in start-ups and academic spinouts focusing on life sciences in the past 15 years.
With a solid base in life sciences, especially in pharmaceutical R&D, the life sciences industry is Sweden's second-largest export industry. Key companies in the market are expanding their regional presence by acquiring various companies. For instance, in February 2023, Swedish CDMO Recipharm began broadening its biologics operations through the acquisition of a Portuguese CDMO, GenIbet. This acquisition provides Recipharm with a platform to manufacture new biological modalities.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Sweden recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Sweden Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
